The significance of multi‑line chemotherapy for advanced gastric cancer: A retrospective analysis

  • Authors:
    • Meiqin Yuan
    • Zhong Shi
    • Zeng Wang
    • Wangxia Lv
    • Yunshan Yang
    • Fangxiao Lu
    • Yazhen Zhao
    • Haijun Zhong
  • View Affiliations

  • Published online on: February 10, 2017     https://doi.org/10.3892/mco.2017.1163
  • Pages: 606-612
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Palliative chemotherapy is known to benefit patients with advanced gastric cancer by palliating symptoms and improving survival. The aim of the present study was to evaluate the efficacy and toxicity of chemotherapy regimens that are commonly used in patients with advanced or recurrent gastric cancer. Patients with advanced or recurrent gastric cancer who were treated by at least two chemotherapy regimens between May 2006 and July 2014 at Zhejiang Cancer Hospital (Hangzhou, China) were retrospectively investigated. Survival was evaluated using the Kaplan‑Meier method. A total of 248 patients were reviewed, and 158 were evaluated in the final analysis, with a median age of 57 years and a Karnofsky performance status score of ≥80. The median progression‑free survival (PFS) time was 168 days for first‑line chemotherapy, 96 days for second‑line chemotherapy, and the median overall survival (OS) time was 356 days. Further analysis revealed that patients with the disease controlled [complete response (CR) + partial response (PR) + stable disease (SD)], no matter whether they received first‑or second‑line chemotherapy, may have had an improved OS compared with patients with disease progression (PD). Patients who were treated with >2 lines of chemotherapy had an improved OS compared those who ceased treatment following failure of the second‑line chemotherapy. The cycle number of chemotherapy that patients received was associated with OS. The site of the primary and metastatic tumors was also associated with OS. Other factors, including gender, age, histological type, whether a radical operation was received, and chemotherapy regimens, had no evident association with survival. The toxicities were generally tolerated. Taken together, the results from the present study have demonstrated that an increased cycle number of effective chemotherapy may prolong the survival of patients with advanced gastric cancer. Differences among the chemotherapy regimens had no clear correlation with survival.
View Figures
View References

Related Articles

Journal Cover

April 2017
Volume 6 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yuan, M., Shi, Z., Wang, Z., Lv, W., Yang, Y., Lu, F. ... Zhong, H. (2017). The significance of multi‑line chemotherapy for advanced gastric cancer: A retrospective analysis. Molecular and Clinical Oncology, 6, 606-612. https://doi.org/10.3892/mco.2017.1163
MLA
Yuan, M., Shi, Z., Wang, Z., Lv, W., Yang, Y., Lu, F., Zhao, Y., Zhong, H."The significance of multi‑line chemotherapy for advanced gastric cancer: A retrospective analysis". Molecular and Clinical Oncology 6.4 (2017): 606-612.
Chicago
Yuan, M., Shi, Z., Wang, Z., Lv, W., Yang, Y., Lu, F., Zhao, Y., Zhong, H."The significance of multi‑line chemotherapy for advanced gastric cancer: A retrospective analysis". Molecular and Clinical Oncology 6, no. 4 (2017): 606-612. https://doi.org/10.3892/mco.2017.1163